

GI Cryo to Present on its Pancreatic Cancer Cryoablation Technology at the Boston Oncology Investor Conference 2019

March 13, 2019

GI Cryo, Inc a start-up med tech company focused on developing and commercializing novel cryoablation technology platform to treat pancreatic cancer and other gastrointestinal related cancers, announced today that John M. Baust, PhD will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Friday, March 15 at 9:35 AM ET. The event will take place at 28 State Street, Boston, MA. Visit www.gicryo.us to learn more about the *FrostBite* technology platform.

About Boston Oncology Investor Conference 2019

The Boston Oncology Investor Conference 2019 at Cowen Healthcare Week is organized by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, McDermott Will & Emery, Torrey Partners, and Marcum. The event sponsor is McDermott Will & Emery. The meeting includes leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science. Information about the conference can be found at www.oncologyinvestorconference.com

About GI Cryo

GI Cryo, Inc. is a private, pre-clinical MedTech company focused on the development and commercialization of an innovative minimally invasive endoscopic ultrasound based cryoablation device for the treatment of pancreatic cancer and other gastroenterological-based diseases. The GastroCS cryoablation console and *FrostBite* EUS Cryocatheter is a novel game changing ablation platform as it offers the ability to increase the speed and effectiveness of “in situ freezing” (cryoablation) allowing for the targeted destruction of cancerous pancreatic tissue in minutes compared to the hours currently required by surgical intervention. GI Cryo has partnered with CPSI Biotech to bring this innovative cryoablation platform to commercialization. GI Cryo is currently pursuing final development, pre-clinical and clinical studies and FDA 510(k) approval in support of technology commercialization.

About CPSI Biotech

CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

Disclosure Notice: The information contained in this release is as of March 13, 2019. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defensible, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI's ability to raise the capital that is required to accomplish the foregoing.

Contacts

CPSI Biotech Contact:

John M Baust, Ph.D., President & Lead Scientist

Kristi Snyder, Ph.D., Director of Operations

Tel: 607-687-8701 Email: contact@cpsibiotech.com